Kalytera Therapeutics (GM) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Kalytera Therapeutics Inc (GM) KALTF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.005 0.00 0.00 0.00 0.005 20:00:00
Bid Price Ask Price Spread Spread % News
0.0105 0.0139 0.0034 24.46% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.005 USD

Kalytera Therapeutics (GM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.63M 525.45M 498.65M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
7.49k $ - 0.00% - -

more financials information »

Kalytera Therapeutics (GM) News

Real-Time news about Kalytera Therapeutics Inc (GM) (OTCMarkets): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KALTF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.090.090.0050.0053,500-0.085-94.44%
1 Month0.026140.2220.0050.0251151107,424-0.02114-80.87%
3 Months0.0140.2540.00010.0199466112,219-0.009-64.29%
6 Months0.03580.2540.00010.0197337148,857-0.0308-86.03%
1 Year0.0370.2540.00010.0281373185,247-0.032-86.49%
3 Years0.09810.45440.00010.0797382194,640-0.0931-94.9%
5 Years0.00390.610.00010.0950793178,3190.001128.21%

Kalytera Therapeutics (GM) Description

Kalytera Therapeutics is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease ("GvHD"). Kalytera is also developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.
Your Recent History
Kalytera T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200709 02:22:09